Johnson & Johnson has agreed to acquire Novira Therapeutics for an undisclosed sum, providing an exit to WuXi PharmaTech, an investor in its $28m series A round.

Biopharmaceutical corporation WuXi PharmaTech is set to exit US-based clinical-stage biopharmaceutical company Novira Therapeutics after pharmaceutical firm Johnson & Johnson agreed to acquire the company.

Financial details of the proposed deal have not been disclosed. The acquisition is expected to close in the fourth quarter of 2015.

Founded in 2009, Novira Therapeutics is developing treatments for chronic hepatitis B virus infections. The potentially fatal disease affects more than 350 million patients and can cause jaundice as well as liver scarring,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?